Hims & Hers Health (NYSE:HIMS) Given New $24.00 Price Target at Piper Sandler

Hims & Hers Health (NYSE:HIMS) had its price target increased by Piper Sandler from $21.00 to $24.00 in a report issued on Monday morning,Benzinga reports. The brokerage currently has a neutral rating on the stock.

A number of other brokerages also recently weighed in on HIMS. TD Cowen reiterated a “buy” rating and set a $28.00 price target on shares of Hims & Hers Health in a report on Wednesday, November 20th. Canaccord Genuity Group lifted their target price on Hims & Hers Health from $28.00 to $38.00 and gave the stock a “buy” rating in a report on Monday, December 2nd. Bank of America cut Hims & Hers Health from a “buy” rating to an “underperform” rating and cut their price target for the stock from $32.00 to $18.00 in a report on Thursday, November 14th. Needham & Company LLC lifted their price objective on shares of Hims & Hers Health from $28.00 to $31.00 and gave the company a “buy” rating in a research note on Monday. Finally, Morgan Stanley initiated coverage on shares of Hims & Hers Health in a research report on Tuesday, December 17th. They set an “overweight” rating and a $42.00 target price on the stock. One research analyst has rated the stock with a sell rating, eight have given a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of “Hold” and an average price target of $24.07.

Hims & Hers Health Price Performance

Hims & Hers Health stock opened at $26.82 on Monday. The stock’s 50 day moving average is $26.73 and its 200 day moving average is $21.53. Hims & Hers Health has a one year low of $8.14 and a one year high of $35.02. The firm has a market cap of $5.86 billion, a P/E ratio of 60.96 and a beta of 1.31.

Hims & Hers Health (NYSE:HIMS) last issued its quarterly earnings results on Monday, November 4th. The company reported $0.32 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.06 by $0.26. Hims & Hers Health had a net margin of 8.19% and a return on equity of 10.97%. The firm had revenue of $401.56 million for the quarter, compared to the consensus estimate of $382.20 million. During the same quarter in the previous year, the company earned ($0.04) EPS. The company’s revenue for the quarter was up 77.1% on a year-over-year basis. Equities analysts anticipate that Hims & Hers Health will post 0.29 earnings per share for the current fiscal year.

Insider Activity at Hims & Hers Health

In other Hims & Hers Health news, insider Michael Chi sold 2,054 shares of the company’s stock in a transaction dated Monday, December 2nd. The shares were sold at an average price of $33.56, for a total value of $68,932.24. Following the completion of the sale, the insider now directly owns 184,947 shares of the company’s stock, valued at approximately $6,206,821.32. This represents a 1.10 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, insider Soleil Boughton sold 2,339 shares of Hims & Hers Health stock in a transaction that occurred on Tuesday, October 15th. The stock was sold at an average price of $20.41, for a total transaction of $47,738.99. Following the transaction, the insider now directly owns 172,274 shares in the company, valued at approximately $3,516,112.34. This represents a 1.34 % decrease in their position. The disclosure for this sale can be found here. In the last three months, insiders sold 1,064,514 shares of company stock valued at $26,712,334. 17.71% of the stock is owned by insiders.

Institutional Trading of Hims & Hers Health

Institutional investors and hedge funds have recently modified their holdings of the business. Renaissance Technologies LLC increased its holdings in Hims & Hers Health by 113.1% during the second quarter. Renaissance Technologies LLC now owns 6,039,408 shares of the company’s stock worth $121,936,000 after buying an additional 3,205,108 shares during the last quarter. State Street Corp increased its stake in shares of Hims & Hers Health by 4.7% during the 3rd quarter. State Street Corp now owns 4,626,543 shares of the company’s stock worth $85,221,000 after purchasing an additional 206,078 shares during the last quarter. Geode Capital Management LLC raised its holdings in shares of Hims & Hers Health by 12.7% in the 3rd quarter. Geode Capital Management LLC now owns 4,289,549 shares of the company’s stock worth $79,029,000 after purchasing an additional 482,177 shares during the period. Wellington Management Group LLP lifted its stake in Hims & Hers Health by 34.5% in the third quarter. Wellington Management Group LLP now owns 3,444,414 shares of the company’s stock valued at $63,446,000 after purchasing an additional 883,230 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its holdings in Hims & Hers Health by 15.1% during the third quarter. Charles Schwab Investment Management Inc. now owns 1,667,422 shares of the company’s stock valued at $30,714,000 after purchasing an additional 218,566 shares during the period. 63.52% of the stock is owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.